ISTA Pharmaceuticals Announces Positive Results for Xibrom
August 30, 2009
ISTA Pharmaceuticals, Inc. has announced positive preliminary Phase 3 results from a confirmatory clinical trial with Xibrom™ (bromfenac ophthalmic solution) 0.09% QD. Xibrom 0.09% QD reached statistical significance in the absence of ocular inflammation 15 days following cataract surgery, and in the elimination of ocular pain one day post surgery. During the study, there were no serious ocular or systemic adverse events and the safety profile is similar to the twice daily formulation.
This phase 3 study was a multi-center, randomized, double-masked, parallel-group study in 299 patients who underwent cataract surgery in one eye. The groups were randomized to either receive Xibrom once a day or placebo and received the eye drops for 14 days after cataract surgery.
The FDA had required ISTA to conduct an additional confirmatory study with the once-daily formulation based on the results from 2 previous studies. This current study confirms the efficacy and safety of Xibrom 0.09% QD. ISTA expects to file a supplemental New Drug Application (sNDA) with the FDA prior to the end of 2009, seeking approval of the Xibrom 0.09% formulation for once-daily treatment for the inflammation and pain following cataract surgery.
Read the release.
You might also enjoy...
- ISTA Pharmaceuticals Announces Phase 3 Results for PROLENSA(TM) Eye Drops for Treatment of Pain and Inflammation After Cataract Surgery
- Once Daily Bromday Drops From ISTA Approved For Cataract Patients
- Acuvail™ From Allergan Receives FDA Approval for Post-Cataract Surgery Treatment
- Is BromSite More Effective Than Bromday Eye Drops For Postoperative Inflammation and Reduction of Ocular Pain?
- Bausch + Lomb Acquiring ISTA Pharmaceuticals
Jump down to form below to submit your own comments